•  
News
  1. Healio
  2. Hematology/Oncology
  3. Hematology Oncology

HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

March 25, 2020
Table of Contents
Cover Story

Palliative care flourishing but ‘significant hurdles’ remain

Point/Counter

Should management of a patient’s physical and psychological symptoms be handled by their oncology team?

Editorial

Goodbye, Clara

Derek Raghavan, MD, PhD

Advanced Practice

Survivorship care plans, evidence- based practice and the ‘Triple Aim’

Dorothy Dulko, PhD, ARNP-C, AOCNP, CCRP

Feature

New child care offerings put oncology meetings at the forefront of work-life balance

Meeting News

Off-the-shelf CAR T-cell therapy induces durable remissions in relapsed, refractory B-cell malignancies

Encorafenib regimens confer quality-of-life, survival benefit in BRAF V600E-mutant metastatic colorectal cancer

Outpatient treatment with lisocabtagene maraleucel feasible for certain patients with non-Hodgkin lymphoma

Acute GVHD less severe after haploidentical transplant with post-cyclophosphamide prophylaxis

Subsequent PFS benefit of apalutamide ‘an indicator of effective early intensive treatment’ in prostate cancer

Tucatinib regimen provides ‘unprecedented’ benefit in heavily pretreated HER2-positive breast cancer

Children with AML from poor neighborhoods face twofold greater risk for death

In the Journals

Low-dose CT screening linked to reduced lung cancer mortality among current, former smokers

Early lenalidomide delays multiple myeloma progression

History of dengue infection increases risk for leukemia

ASCO names refinement of surgical cancer treatment ‘Advance of the Year’

FDA News

FDA grants orphan drug designation to several hematology/oncology therapies

FDA finds ‘insufficient evidence’ to link cellphone radiation to cancer

FDA approves Padcev for urothelial cancer

Four regimens receive priority review for lung cancer indications

FDA approves Monoferric injection for iron deficiency anemia

FDA grants breakthrough therapy designation to APR-246, azacitidine combination for myelodysplastic syndrome

NIH selects five Lasker Clinical Research Scholars

Hematopoietic stem cell researcher to receive lecture award

City of Hope appoints chair of hematology and hematopoietic cell transplantation